FATE FY 2023 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$158M

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$64M-34.0% YoY

Gross Profit

-$94M-147.4% margin

Operating Income

-$191M-299.9% margin

Net Income

-$161M-253.3% margin

EPS (Diluted)

$-1.64

Cash Flow

Operating Cash Flow

-$132M

Free Cash Flow

-$138M

Stock-Based Comp.

$43M

Balance Sheet

Total Assets

$506M

Total Liabilities

$138M

Stockholders' Equity

$368M

Cash & Equivalents

$42M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$64M	$96M	-34.0%
Gross Profit	-$94M	$83M	-213.5%
Operating Income	-$191M	-$308M	+38.2%
Net Income	-$161M	-$282M	+42.9%